APOC new treatment for NET
Innovative treatment for neuroendocrine Tumors (NETs).
Product available for licensing out.
APOC is a new drug product containing octreotide, the best in class somatostatin analogue (SSA) and the cornerstone of therapy for patients with Neuroendocrine Tumors (NETs) and acromegaly. Somatostatin analogue products are the first line reference treatment for these diseases with a $2 billion market and a high double-digit growth.
APOC is designed to provide a better efficacy thanks to improved bioavailability, controlled PK and an optimal safety profile. Thanks to its product performance and characteristics, APOC is the best and only convenient product adaptable to all patient’s needs, offering a personalized treatment.
APOC is currently under clinical evaluation. ASCIL is seeking for partner for next stage of development.
Developed by Web4Bio